Sep 10, 2026 3-5pm ET
Thursday on The Robert Scott Bell Show:
Hour 1
Special Guest: Jonathan Emord
For the past 37 years, Jonathan W. Emord has litigated against the federal bureaucracy, winning over and over again. Ron Paul calls Jonathan “an expert in constitutional theory and history” and “an expert litigator with a long string of legal victories over the federal bureaucracy.” George Noory calls him “a Knight in Shining Armor” and “a warrior out to save our rights.” Congressmen Dan Burton and John Doolittle describe him as “an intellectual warrior for the rights and freedoms of people in America.” Jonathan has a unique, detailed knowledge of the federal bureaucracy, the deep state. He knows how to defeat it. Jonathan graduated from the University of Illinois (BA, political science and history, 1982) and DePaul University College of Law (JD, 1985). He served as an attorney in the Federal Communications Commission during the Reagan administration. A leading constitutional law and litigation expert, he is the author of five critically acclaimed books. He has won more cases against the Food and Drug Administration in federal court than any other attorney in American history, earning him the nickname “FDA Dragon Slayer.” He is a columnist for Townhall.com, PJ Media.com, Americangreatness.com, and the U.S.A. Today Magazine. He frequently appears on national radio and television programs. He is married to Sheryl Emord, and they have two children, twins Justice and Angelica. They reside in Clifton,
The PREP Act: Unchecked Power, Zero Accountability, and a Path Forward Robert W. Malone writes that the Public Readiness and Emergency Preparedness Act is among the broadest grants of legal immunity in U.S. history, allowing the HHS Secretary, beginning with a February 2020 COVID-19 declaration, to shield manufacturers, distributors, and administrators of countermeasures from lawsuits except for willful misconduct causing death or serious injury, a standard he calls extremely hard to meet, so injured people must use the Countermeasures Injury Compensation Program, which he describes as hard to navigate and limited in relief. He says the Secretary can declare emergencies, define countermeasures, covered persons, and timeframes without required congressional consultation or judicial review, and that declarations preempt state licensing, age rules, scope of practice, and cross-state licensure, including allowing pharmacists, technicians, students, and holders of expired licenses to give shots and drugs. Trump and Biden administrations amended the COVID declaration at least 12 times, he writes, expanding it to routine childhood vaccines, seasonal flu shots, respiratory protective equipment, and interstate telehealth. The Third Amendment covered diseases “that may have been caused by COVID-19,” including falling childhood vaccination rates. The Fourth incorporated HHS advisory opinions and treated CDC guidance as action by an “authority having jurisdiction.” The Eleventh and Twelfth Amendments extended protections through Dec. 31, 2024, then Dec. 31, 2029, more than six years after the Section 319 public health emergency ended in May 2023, a choice he calls discretionary. Citing June 2024’s Loper Bright Enterprises v. Raimondo and Relentless, Inc. v. Department of Commerce, which ended Chevron deference, he quotes Chief Justice Roberts that courts must decide independently what the law means and notes Justice Thomas’s separation-of-powers concurrence. He argues expansive definitions, state-law preemption, post-emergency extensions, and nonbinding opinions are vulnerable under independent statutory reading and the major questions doctrine, while basic emergency declarations and contract-based immunity may stand. He lists Secretary options: set an earlier end date than 2029, narrow diseases and persons back to COVID-only and drop “qualified persons” such as students and expired-license holders, rescind the Third Amendment’s pediatric-vaccine reach and telehealth provisions, stop treating advisory opinions as part of the declaration, clarify that contract immunity ends when the government stops buying countermeasures, and let provisions sunset. He frames restoration of court access and state boards as federalism and individual rights, not anti-vaccine policy, and says six years after the emergency began and years after vaccines were widely available the shields no longer serve an emergency purpose, so the question is political will, not legal power.
Americans are Falling into the Socialist Trap by Blaming Capitalism for the Damage of Statism. Daniel Lacalle writes on Sept. 4, 2026, that young Americans blaming capitalism for housing costs, weak real wages, poor savings returns, and stalled mobility are living the failure of statism, the replacement of civil society, markets, savings, and choice by political control, spending, regulation, taxation, and monetary intervention, not free markets. He calls the predatory state in his book The New Global Economic Order the extreme form, extracting wealth to sustain politicians and clients. Big government, high taxes, money printing, and cronyism are not capitalism, he says, while socialism is judged on intentions not results, giving elites moral cover while making the poor more dependent, after which the state is too large to reverse and uses repression. France, with government spending over 57 percent of GDP, shows stagnation, discontent, and debt, and he says no economy fixed affordability by political control and monetary financing of deficits. The public sector is politician-run, not “the public,” and nationalization is politicization. Since 2008 the U.S. and other developed economies have been dominated by deficits, debt, taxes, debasement, regulation that protects insiders, and intervention, which is why some wealthy people back socialism to kill merit and competition. Cronyism follows statism. He says socialist leaders stay rich while the system needs the poor to stay poor, replaces market inequality with political inequality, ignores economic calculation, and uses currency debasement to expropriate the private sector. IMF figures put advanced-economy general government spending at 40.7 percent of GDP in 2026 and OECD EU members at 49.3 percent. Advanced-economy fiscal deficits were 4.4 percent of GDP in 2025 and a projected 4.8 percent in 2026. Global gross public debt was 93.9 percent of GDP in 2025 and is projected at 100 percent by 2029. Central-bank balance sheets peaked at $8.97 trillion at the Fed in April 2022, €8.84 trillion in the Eurosystem in June 2022, and ¥764.8 trillion at the Bank of Japan in August 2024, or 34.5 percent, 64.2 percent, and 125.8 percent of GDP, and remain large in 2026. He says that punishes savers and wages, inflates assets, and disguises sovereign risk. Artificial money is never neutral. OECD work ties housing costs to zoning and supply limits, yet socialist answers add subsidies and controls. China and the Nordics, he argues, grew after abandoning socialist controls, not because socialism works. He calls “democratic socialism” an oxymoron and “true socialism has never been tried” a lie, saying socialism is a dreadful idea executed fully, and that blaming capitalism for intervention’s damage is a strategy to sell the trap. Prosperity needs smaller government, budget control, open money, fewer barriers to business and housing, and taxes that reward work and saving.
“You Better Get Ready For… War”: Socialists Call For “War In The Streets” & The End Of Capitalism Jonathan Turley writes, republished on ZeroHedge, that socialists at a Chicago Marxism conference and related events are planning a next stage that excludes the Democratic establishment, as the Democratic Socialists of America reaches historic size and socialist candidates win while figures such as Sen. Chuck Schumer and Gov. Gavin Newsom pander to the movement. UC Santa Barbara history professor Butch Ware, listed as a professor of Africa and Islam and paid more than $211,000, said Democrats “must be destroyed,” that they “cannot be reasoned with,” that “you cannot call yourself a revolutionary and not be talking about training with weapons,” and, in an X video, that some “clickety-clack revolutionaries have never been in a f*cking gunfight,” adding “Y’all ain’t nowhere near ready for a war in the streets” and “You better get ready for both kinds of war.” Ware has posted that New York City Mayor Zohran Mamdani and Senate nominee Abdul El-Sayed are too restrained and used to contain radicalism. Turley cites socialists chanting at House Minority Leader Hakeem Jeffries after a win, Hasan Piker calling for a purge of Democratic moderates, and Darializa Avila Chevalier saying a “big tent doesn’t pay your rent” while democratic socialism does. At Socialism 2026, CUNY professor Ruth Gilmore said “It’s capitalism we’re after” and that capitalism is racial and produces sexual and gender boundaries. University of Chicago professor Eman Abdelhadi, half-sister of Michigan Senate candidate Abdul El-Sayed, has denounced the university as colonialist while teaching there to bring the system down, offered an “October 7th blessing” a year after the attack, was previously arrested for spitting on officers, and said “I’ll see you on the streets.” Michigan 7th District candidate William Lawrence has called for ending borders, the nation-state, and capitalism and told a moderate Democrat to “hurry up and die.” Rep. Laura Gillen (D-N.Y.) said Democrats would block “crazy” DSA measures from reaching the floor. Turley argues leaders such as Newsom campaigning that capitalism is “not working,” Texas Senate candidate James Talarico calling to “dismantle” capitalism, and Kamala Harris treating Supreme Court loyalty as “nostalgia” repeat a historical delusion that elites can use mobs against opponents and survive, and that putting elections first endangers institutions and capitalism and embraces the “mobocracy” the Founders warned against, a theme of his book Rage and the Republic. He notes UCSB earlier had a professor who pleaded guilty to assaulting pro-life advocates and was later honored by the University of Oregon.
FDA Misses Deadline as Sweeping Federal Cannabinoid Ban Approaches The ANH Team writes on Sept. 3, 2026, that the FDA missed a Feb. 10 deadline to list which cannabinoids count toward a new 0.4-milligram-per-container hemp limit and to define “container,” leaving farmers and businesses without rules more than six months later as a Congressional Research Service update found nothing published as of August 2026. Congress put the restrictions in the fiscal year 2026 appropriations law signed in November 2025 and gave FDA 90 days to publish lists of naturally occurring cannabis cannabinoids, naturally occurring THC-class cannabinoids, and other cannabinoids known or marketed to act like THC, plus a container definition. Unless Congress acts, the new hemp definition takes effect Nov. 12, 2026, and ANH says many non-intoxicating full-spectrum CBD oils with trace THC could vanish, comparing the risk logic to banning coffee because high-dose caffeine can harm. The group supports limits on dangerous synthetics, adulterated goods, deceptive marketing, and sales to minors but not wiping out adult wellness products. Congress approved a funding measure delaying most hemp restrictions until Dec. 11 while letting a synthetic-derivative ban proceed, awaiting President Trump’s expected signature, which ANH calls a one-month stopgap. The bipartisan Hemp Planting Predictability Act, S. 3686 and H.R. 7024, would stretch implementation from one year to three. Sens. Ron Wyden and Jeff Merkley’s Cannabinoid Safety and Regulation Act, S. 3474, would set manufacturing, testing, labeling, registration, and age rules, create a federal path for cannabinoid dietary supplements, allow truthful substantiated structure-function claims, and tools to pull dangerous synthetic and semi-synthetic cannabinoids. ANH says Congress should regulate by actual risk rather than treat trace natural hemp like high-dose intoxicants and that the missed FDA deadline shows access must be written into statute, and it asks readers to tell members to back both bills.Hour 2
Changing What We Ask Of The FDA Srijith Rangan, a Brown University student and 2026 Center for Modern Health Summer Fellow from New Hampshire, writes in September 2026 that about 5 percent of roughly 10,000 known rare diseases have an FDA-approved treatment, so nearly 30 million Americans with rare conditions face about one-in-twenty odds of a medicine clearing the agency, citing GAO-25-106774. Last February Atara Biotherapeutics and Pierre Fabre’s Ebvallo (tabelecleucel), a cell therapy for a post-transplant rare cancer that hits about 500 U.S. patients a year and is usually fatal in weeks or months, was recommended for approval by FDA internal reviewers, STAT News reported Feb. 25, 2026, then rejected for “deficient clinical data” in what a former staffer called a complete reversal, though the drug is approved and sold in Europe. A year earlier Sarepta’s Elevidys, a Duchenne muscular dystrophy gene therapy approved in 2023, faced a July 2025 move by an FDA official to suspend it after multiple patient deaths, thin benefit, and a walking-test gain of a fraction of a second versus placebo at $3.2 million per infusion with much revenue expected from Medicaid, after which company and advocate pressure reportedly led the reviewer to leave the agency temporarily, as discussed in Jared Rhoads’s May 2026 Center for Modern Health proposal. Rangan argues FDA approval is the on-ramp to Medicare, Medicaid, and private coverage, so it opens a taxpayer pipeline that is costly and politically hard to close, even though cost is not supposed to drive approvals. He proposes that for drugs sold only to private patients and insurers the FDA confirm basic safety while patients, physicians, and insurers judge efficacy through informed consent, tort liability, and coverage choices, and that Medicare or Medicaid inclusion require safety, efficacy, and cost review because public programs spend tax money in a non-competitive market. He analogizes off-label prescribing, which already splits the freedom to use an unapproved treatment from who must pay. The status quo, he says, assumes regulators beat informed private parties at tradeoffs when no public funds are at stake. For the roughly 500 patients a year in the Ebvallo disease and families watching a $3.2 million therapy become political, he writes the fix is a narrower FDA job, decide if it is safe and let the market decide if it is worth buying, reserving harder efficacy judgments for public-payer cases.
Special Guest: Jonathan and Jenny Rose
Jonathan Rose is William R. Kenan Professor of History at Drew University, where he directs the graduate program in History and Culture. He is also the surviving husband of the vaccine injury activist Gayle DeLong, and he edited and published her diaries under the title Love in the Age of Autism (Anthem Press, 2025). Prof. Rose was the founding president of the Society for the History of Authorship, Reading and Publishing and a founding editor of the journal Book History. His book The Intellectual Life of the British Working Classes (2001; 3rd ed., 2021) won the Longman-History Today Historical Book of the Year Prize, the American Philosophical Society Jacques Barzun Prize in Cultural History, the British Council Prize of the North American Conference on British Studies, the SHARP Book History Prize, and the New Jersey Council for the Humanities Book Prize. His other publications include The Edwardian Temperament 1895-1919 (1986), The Revised Orwell (1991), The Holocaust and the Book: Destruction and Preservation (2001), The Literary Churchill: Author, Reader, Actor (2014), and Readers’ Liberation (2018). With Simon Eliot, he edited A Companion to the History of the Book (2nd ed., 2019); and with Mary Hammond, he edited The Edinburgh History of Reading (2020). His work has been translated into Chinese, Russian, Italian, Flemish, Czech, and Lithuanian. His current research focuses on the female readers of Playboy.
Jennifer Rose is an author with autism, a film critic, and a community builder from New Jersey who has been writing since she was nine. She is the author of Manimal Crackers (GenZ Publishing, 2026), in which a girl named Jessica Rothenberg finds an unlikely mentor in the ghost of a short-lived 1980s TV star, and It’s Not a Perfect World, But I’ll Take It (Skyhorse Publishing, 2016), fifty unsugarcoated life lessons on growing up on the spectrum. She is currently working on three more manuscripts. A graduate of St. Elizabeth University and currently studying Library Science at William Paterson University, she writes blog posts and reviews movies at jenniferroseauthor.com, including all 250 in honor of the country’s 250th birthday. She is also building Autonomy, an online literary magazine and hub where writers on the autism spectrum can share their art, writing, and musings with the world.
Welcome back to another “Homeopathic Hits” episode on The Robert Scott Bell Show!
Today’s Homeopathic Hit is Mitchella repens, commonly known as Partridge-berry.
Boericke presents this remedy where bladder symptoms accompany uterine complaints, especially uterine congestion, dysmenorrhoea, uterine haemorrhage, and irritation at the neck of the bladder with urging to urinate.
Download the Information Sheet
Remember Friends, The Power to Heal is Yours!
